- Results from the pivotal Phase 3 ENVISION trial studying primary chemoablation with UGN-102 (mitomycin) for intravesical solution in patients with recurrent low-grade intermediate-risk non-muscle-invasive bladder cancer (LG-IR-NMIBC) will be presented as a late-breaking oral presentation
- The Phase 3 ATLAS trial comparing the efficacy and safety of intravesical chemoablation with UGN-102 with or without subsequent TURBT, to TURBT alone in patients with LG-IR-NMIBC will be presented in a digital poster session
PRINCETON, N.J.--(BUSINESS WIRE)--Nov. 13, 2023-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, will highlight data from two key Phase 3 trials evaluating UGN-102, an investigational treatment in development for LG-IR-NMIBC at the 2023 Society of Urologic Oncology (SUO) annual meeting, November 28-December 1 in Washington D.C. These data presentations further UroGen’s mission of developing and commercializing innovative treatments for urothelial and specialty cancers that provide patients with novel non-surgical options to fulfill the unmet needs that exist with current standards of care.
“The ATLAS and ENVISION Phase 3 clinical trials broaden our understanding of potentially using a new approach to treat LG-IR-NMIBC,” says Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “We’re particularly excited that the SUO selected the ENVISION study as one of only two late-breaking trials designated for oral presentations, which we believe further reinforces its potential in advancing bladder cancer treatment. We are optimistic for what the future may hold for LG-IR-NMIBC patients who suffer from this highly prevalent and recurrent disease.”Key highlights of UGN-102 data accepted by SUO:
Source: UroGen Pharma Ltd. (2023). UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology [Press release]. https://investors.urogen.com/news-releases/news-release-details/urogen-will-present-scientific-advances-bladder-cancer-annual.